Calan SR (Verapamil sustained-release) is a cardiovascular agent used for the continuous management of conditions involving elevated blood pressure and abnormal heart rhythms. Its therapeutic utility is based on its role in addressing three primary symptomatic domains. The medication is relevant in clinical settings marked by increased physiological stress and helps address symptom clusters that may become intense or disruptive.

---

Therapeutic Focus and Symptom Relief

Calan SR plays a role in managing essential hypertension; specific supraventricular tachyarrhythmias, such as atrial fibrillation and atrial flutter; and chronic chest pain symptoms associated with stable angina pectoris and vasospastic angina. This supportive approach is applied in scenarios where short-term symptomatic assistance is needed.

“The therapeutic approach may help ease the impact of cardiovascular stress on general comfort.”

By assisting with the control of an overly rapid heartbeat and contributing to a sustained lowering of high arterial pressure, the medication may help reduce the chronic strain on the body. This supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Relief for Cardiac Pain and Palpitations The medication is commonly used to help with symptoms related to angina attacks, including their frequency, and assists with controlling rapid heart rate fluctuations, which supports general well-being during symptomatic phases.

Regulatory References

1. Verapamil: MedlinePlus Drug Information

Calan SR (Verapamil extended-release) eligibility is strictly determined by a patient’s existing cardiovascular and organ function status, as defined in regulatory documents. Use is contraindicated (absolutely forbidden) in patients with specific severe cardiovascular conditions.

Contraindicated Populations (Absolute Non-Eligibility)

Non-eligibility includes severe left ventricular dysfunction, hypotension (systolic pressure less than 90 mmHg), or cardiogenic shock. The medicine is also forbidden for patients with Sick Sinus Syndrome or Second- or Third-degree AV block, unless a functioning artificial ventricular pacemaker is present. A final absolute contraindication applies to those with atrial flutter or fibrillation combined with an accessory bypass tract (e.g., Wolff-Parkinson-White syndrome).

---

Restricted and Conditional Use

The regulatory label imposes conditional use restrictions based on organ function. Patients with impaired hepatic function or impaired renal function require cautious use and monitoring due to the drug's metabolism and elimination profile. Use is not established in pediatric patients; safety and effectiveness have not been confirmed in this age group. Geriatric patients may exhibit greater sensitivity and require special consideration.

Interactions with other medicines and products

Calan SR (verapamil) can interact with numerous prescription and non-prescription products due to its effects as a moderate inhibitor of the CYP3A4 enzyme and a P-glycoprotein (P-gp) transporter inhibitor. These interactions can significantly alter the concentration of both verapamil and co-administered drugs.

Contraindicated Combinations

Co-administration with specific drugs is strictly prohibited due to the risk of serious adverse effects. These include dantrolene and several sensitive CYP3A4 substrates, such as pimozide, flibanserin, and lonafarnib. Intravenous administration of verapamil and intravenous beta-blockers must not occur in close proximity.

Pharmacokinetic and Pharmacodynamic Effects

Verapamil increases the concentration of many co-administered medicines that are metabolized by CYP3A4. This requires dose limitation for drugs like simvastatin and lovastatin to reduce the risk of toxicity. Conversely, drugs that induce CYP3A4, such as rifampin, can substantially reduce verapamil's effectiveness by lowering its concentration.

Pharmacodynamic interactions with other cardiovascular depressants, including oral beta-blockers and other antiarrhythmics, can result in additive effects on cardiac conduction.

Food and Population Considerations

The interaction profile also includes substances that alter verapamil's bioavailability. Grapefruit juice is documented to increase verapamil levels and should be avoided. The dosage and interaction risk should be monitored more closely in patients with hepatic impairment and in the elderly, as reduced drug clearance may lead to increased drug exposure.

Biological Target and Cellular Interaction

Calan SR (verapamil) functions as a non-dihydropyridine calcium channel blocker. Its mechanism involves binding specifically to the L-type calcium channels located on the membranes of myocardial and vascular smooth muscle cells. This interaction inhibits the transmembrane influx of extracellular calcium ions.

Cardiovascular Mechanistic Cascade

The resulting reduction in intracellular calcium concentration diminishes the availability of calcium for the contractile machinery. This process leads to reduced myocardial contractility and causes the relaxation of vascular smooth muscle.

Physiological Consequences

The downstream physiological effects include a lowering of systemic vascular resistance and a reduction in cardiac oxygen demand. Additionally, this action modulates the electrophysiological properties of the heart by decreasing the rate of impulse conduction through the atrioventricular (AV) node.

Calan SR is administered via the oral route as an extended-release tablet. The high-level usage pattern is defined by a standardized initial dose, typically 180 mg once daily for adults with essential hypertension. A lower initial dose of 120 mg once daily is specified for certain sensitive populations, such as older adults or individuals of small stature. Dosing is then titrated upward based on response, usually evaluated at weekly intervals, to a maintenance range that can extend up to a maximum of 480 mg per day. Higher total daily dosages may necessitate dividing the total amount for administration twice daily (every 12 hours).

The use of the sustained-release tablet requires specific administration conditions. The tablet must be swallowed whole and not be crushed or chewed to maintain the integrity of its prolonged-release mechanism, which is essential for consistent blood concentration. Furthermore, the tablet should be administered with food to ensure predictable absorption characteristics. The once-daily regimen is generally intended for chronic management, with the initial dose typically scheduled for intake in the morning.

Dosage modification is recommended for patients with hepatic impairment, with requirements sometimes calling for a dose reduction to approximately one-third of the normal oral daily dose, based on the drug's metabolism. Regarding timing, if a dose is missed, general instructions indicate to resume the regular schedule and under no circumstances to double the dose.

Research evidence / Overview of studies for Calan SR

Evidence for Use in Essential Hypertension (High Blood Pressure)

Research was conducted in adults with diagnosed essential hypertension, including those with coexisting cardiovascular conditions. Large-scale Randomized Controlled Trials (RCTs) were conducted over several years, including those that involved adults aged 50 and older. These trials monitored both systolic and diastolic blood pressure (BP), including the BP profile over a 24-hour period. Furthermore, studies monitored outcomes related to systemic or functional imbalance, including the occurrence of specific cardiovascular events.

Findings describe patterns observed in the studies, such as measured changes in BP levels. Pharmacokinetic studies report patterns related to drug levels over time. Certainty remains low regarding the consistency of the link between the drug concentration in the body and certain cardiac electrical markers observed during chronic administration.

---

Evidence for Use in Chronic Angina Pectoris

Studies explored the use of the drug in conditions characterized by fluctuating or episodic manifestations of chest pain, including chronic stable and vasospastic angina. The research design included controlled studies and Placebo-Controlled Exercise Tolerance Trials. Studies monitored measures of daily functioning or activity level, specifically measuring total exercise time on a treadmill and the time until the onset of anginal chest pain during exertion.

Placebo-controlled trials reported how symptoms evolved in the observed populations, describing measured changes in exercise duration. However, some evidence is limited as it was derived from settings where follow-up durations were limited, often relying on short-term cross-over trials of less than four weeks.

---

Evidence for Use in Supraventricular Tachyarrhythmias

Research in this area examined conditions associated with acute or disruptive episodes of rapid heart rhythm (such as PSVT), with studies designed to measure rhythm patterns. Studies monitored outcomes related to systemic or functional imbalance, specifically measuring the recurrence rate of PSVT episodes and tracking changes in the heart’s electrical conduction parameters.

Electrophysiological reports described observed changes in measured electrical parameters. Clinical trials reported the measured rate of return to a normal rhythm. Limited information is available for long-term outcomes, as the primary research focus for acute rhythm management has been on the immediate-acting intravenous formulation rather than the oral extended-release product.

---

What Remains Uncertain: Evidence Gaps

The current evidence landscape highlights areas where more research is needed. Comparative evidence is lacking in some areas, and long-term effects are not fully established across all conditions, as follow-up durations were limited in certain early trials. Data for certain groups remain insufficient, especially regarding the long-term use in patients with compromised liver function.

Key Studies & References

1. Verapamil: MedlinePlus Drug Information (NIH)

Common questions about Calan SR (FAQ)

Q: What's the difference between Calan SR and regular Calan?

A: Calan SR is the sustained-release or extended-release formulation of the active ingredient, verapamil. This design allows the medication to be released slowly over an extended period. The term 'regular Calan' typically refers to the immediate-release formulation, which releases the medication quickly and requires more frequent dosing.

---

Q: How quickly should I expect Calan SR to start lowering my blood pressure?

A: The full therapeutic effect of Calan SR is not usually immediate. According to official dosing guidelines, adjustments to the dose are typically assessed at weekly intervals, which indicates that the full, stable benefit of the medication is realized over several weeks of consistent use.

---

Q: What's the difference between Calan SR and other drugs like amlodipine?

A: Both Calan SR (verapamil) and amlodipine are calcium channel blockers, but they belong to different chemical groups. Calan SR is a non-dihydropyridine type, meaning it primarily influences the heart's electrical conduction system and heart muscle. Drugs like amlodipine are typically dihydropyridine types, which mainly affect the blood vessels.

---

Q: Does Calan SR have a withdrawal effect if I stop taking it suddenly?

A: Regulatory information does not explicitly define a 'withdrawal syndrome' for Calan SR. However, abruptly stopping certain heart and blood pressure medications may lead to a rebound effect or changes in the underlying condition. Changes to any medication schedule should always be discussed with a healthcare provider.

---

Q: What should I do if my side effects don't go away after a few weeks?

A: Official guidelines recommend that patients contact a healthcare provider if they experience symptoms that concern them or if common side effects, such as constipation, headache, or dizziness, do not subside after starting treatment. A healthcare provider can offer an evaluation of the symptoms based on clinical guidance.

---

Q: Can Calan SR make you feel more tired than usual?

A: Yes, regulatory documents list fatigue and general weakness/tiredness as adverse reactions that have been reported in connection with the use of verapamil.

---

Q: Are there any generic versions of Calan SR available?

A: Yes, the active ingredient in Calan SR, Verapamil Hydrochloride, is widely available in generic extended-release tablet and capsule forms from various manufacturers.

---

Q: How does Calan SR interact with alcohol?

A: Official regulatory documents indicate that consuming alcohol while taking verapamil can increase the blood levels and intoxicating effects of alcohol. A discussion of alcohol consumption with a healthcare provider is generally recommended.

---

Q: Does Calan SR cause weight gain?

A: While weight gain is not listed as a primary side effect, the medication is known to cause peripheral edema, which is the swelling of the ankles or feet. This fluid retention may contribute to sudden or unexplained weight changes.

---

Q: What are the signs of a serious allergic reaction to Calan SR?

A: Signs of a serious reaction may include trouble breathing, swelling of the throat or tongue, hives, or a rash accompanied by fever or chest tightness. The appearance of severe symptoms warrants immediate professional medical attention.

---

Q: Can Calan SR be used to treat pulmonary hypertension?

A: No, according to official regulatory indications, pulmonary hypertension is not listed as an approved use for Calan SR. The approved indications are for hypertension (high blood pressure), angina (chest pain), and certain supraventricular tachyarrhythmias (heart rhythm problems).

---

Q: Is it important to take Calan SR at the same time every day?

A: Yes, the regulatory guidelines for extended-release medications emphasize the importance of taking them at the same time every day. This consistent timing is necessary to maintain steady and predictable blood concentrations of the drug for chronic management.

---

Q: Can Calan SR affect blood sugar levels in people with diabetes?

A: While changes in blood sugar are not generally listed as a common adverse reaction in the official product information, some clinical literature suggests that patients with diabetes may require careful monitoring when using verapamil.

---

Q: Does Calan SR interact with common cold and flu medications?

A: Official documents caution that verapamil may interact with many non-prescription products due to its effect on liver enzymes. Medications containing decongestants or other stimulants can be of particular concern, and review of their use with a healthcare provider is advisable.

---

Q: Can I take Tylenol or Advil while on Calan SR?

A: Official warnings note interaction risk with non-prescription products. Specifically, non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen (Advil) may potentially reduce the blood-pressure-lowering effect of verapamil. A review of all common over-the-counter medications, including Tylenol (acetaminophen), with a healthcare provider is advisable.

---

Q: How does Calan SR affect potassium levels?

A: Calan SR is a calcium channel blocker, meaning its main action is on calcium. While its core mechanism does not focus on potassium, some scientific observations indicate it can affect certain potassium ion channels (K+ currents) in the heart. This effect is not listed as a common clinical effect or warning.

---

Q: Is it okay to take Calan SR with multivitamins?

A: Some multivitamins that contain minerals may potentially reduce the absorption or effects of verapamil. It is generally recommended that a healthcare provider be informed of all supplements, including vitamins and herbal products.

How to Store and Dispose of Calan SR

Calan SR (verapamil hydrochloride extended-release tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product requires protection from light and moisture, and must be kept from freezing or exposure to excess heat.

Container and Child Safety The tablets must be stored in the container they were dispensed in, which should be kept tightly closed. The medication must be secured out of the reach of children to prevent accidental poisoning.

Disposal Requirements Do not keep outdated or unneeded medicine. Disposal must be conducted according to local, national, and international regulations. The medication should not be flushed down the toilet or sink, and environmental release must be avoided.